Project/Area Number |
15K15444
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Radiation science
|
Research Institution | Tohoku University |
Principal Investigator |
Iwata Ren 東北大学, サイクロトロン・ラジオアイソトープセンター, 名誉教授 (60143038)
|
Co-Investigator(Kenkyū-buntansha) |
高橋 和弘 秋田県立脳血管研究センター(研究部門), その他部局等, 研究員 (20370257)
|
Co-Investigator(Renkei-kenkyūsha) |
ISHIKAWA Yoichi 東北大学, サイクロトロン・ラジオアイソトープセンター, 助手 (60361200)
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 放射性金属 / 電気化学的濃縮 / ペプチド・抗体標識 / 標識技術 / 放射性金属核種 / 電極反応 / ペプチド・タンパク質標識 |
Outline of Final Research Achievements |
The present study was aimed to develop a challenging method for separating radioactive metal ions in a small space by electrochemical adsorption and desorption on the Pt/carbon electrode and for labeling peptides or antibodies with recovered radioactive metals by chelating reactions. [18F]Fluoride was concentrated and then converted in >75% to A][18F]2+ with Al3+ in the narrow channel of an electrochemical chip. Recovery yields, however, were varied independently on applied voltage and time probably due to the surface conditions of the carbon electrode. A custom-made target chamber was developed and successfully tested for producing 64Cu by the 64Ni(p,n)64Cu reaction with the HM12 cyclotron at CYRIC. Transtuzumab and Cetuximab were chosen as a candidate antibody. They were modified with DOTA-NHS-ester as a chelating agent and a protocol suitable for the preparation of 64Cu-DOTA-Transtuzumab and 64Cu-DOTA-Cetuximab in a small scale was established.
|